OTCMKTS:MLCPF Medipharm Labs (MLCPF) Stock Price, News & Analysis $0.06 +0.00 (+2.14%) As of 05/29/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Medipharm Labs Stock (OTCMKTS:MLCPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medipharm Labs alerts:Sign Up Key Stats Today's Range$0.06▼$0.0650-Day Range$0.05▼$0.0752-Week Range$2.57▼$2.57Volume39,499 shsAverage Volume181,345 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medipharm Labs Corp. is a Canadian contract development and manufacturing organization (CDMO) specializing in pharmaceutical-grade cannabis formulations. The company partners with licensed producers and brand owners to deliver science-based product development, formulation and manufacturing services across a variety of dosage forms. Its capabilities include the design and production of oils, capsules, tablets, soft gels, topical creams and vape cartridges, leveraging proprietary formulation technologies such as nanoemulsions and controlled-release systems. Medipharm Labs operates a fully integrated, Good Manufacturing Practice (GMP) certified facility, offering analytical testing, stability studies and scale-up support from pilot to commercial volumes. Headquartered in Laval, Quebec, Medipharm Labs serves clients in Canada and select international markets where cannabis derivatives are permitted. The company’s facility infrastructure and analytical laboratories enable compliance with regulatory requirements in multiple jurisdictions, supporting both medical and adult-use applications. Founded in the mid-2010s, Medipharm Labs has built a portfolio of patented cannabis formulation technologies and matured its service offering under the leadership of Chief Executive Officer David Stewart. The management team draws on pharmaceutical industry experience to drive innovation in cannabinoid product development and to scale manufacturing operations in response to evolving market demand.AI Generated. May Contain Errors. Read More Receive MLCPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medipharm Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLCPF Stock News HeadlinesMediPharm Labs Achieves Double-Digit Revenue Growth in Q3 2025November 13, 2025 | msn.comMediPharm Labs Corp. (LABS:CA) Q3 2025 Earnings Call TranscriptNovember 13, 2025 | seekingalpha.comMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.May 30 at 1:00 AM | Behind the Markets (Ad)MediPharm Labs Reports Strong Q2 2025 GrowthAugust 15, 2025 | msn.comQ2 2025 Medipharm Labs Corp Earnings Call TranscriptAugust 14, 2025 | gurufocus.comMediPharm lays out the implications for possible new U.S. cannabis reschedulingAugust 13, 2025 | msn.comLABS:CA MediPharm Labs Corp.April 11, 2025 | seekingalpha.comMediPharm Labs Shows Strong Q3 GrowthNovember 15, 2024 | markets.businessinsider.comSee More Headlines MLCPF Stock Analysis - Frequently Asked Questions How have MLCPF shares performed this year? Medipharm Labs' stock was trading at $0.0540 at the beginning of 2026. Since then, MLCPF shares have increased by 6.1% and is now trading at $0.0573. How do I buy shares of Medipharm Labs? Shares of MLCPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceuticals - Other Sub-IndustryN/A Current SymbolOTCMKTS:MLCPF CIKN/A Webwww.medipharmlabs.com Phone705-719-7425FaxN/AEmployees28Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:MLCPF) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medipharm Labs Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Medipharm Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.